Royalty Pharma is pleased to acquire a synthetic royalty on Geron’s Rytelo for $125 million. Rytelo is an FDA-approved, first-in-class telomerase inhibitor to treat low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia (LR-MDS with TD anemia). Read more here:?https://lnkd.in/eZdNZUij
关于我们
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson’s Imbruvica, Astellas’ and Pfizer’s Xtandi, Biogen’s Tysabri, Johnson & Johnson’s Tremfya, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates.
- 网站
-
https://www.royaltypharma.com
Royalty Pharma的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- New York，New York
- 类型
- 上市公司
- 创立
- 1996
地点
-
主要
获取路线
110 East 59th street
33rd floor
US，New York，New York，10022
Royalty Pharma员工
动态
-
Royalty Pharma is excited to announce an agreement with Syndax to acquire a synthetic royalty on Niktimvo for $350 million. Niktimvo is an FDA-approved, first-in-class anti-CSF-1R antibody approved for the treatment of chronic graft-versus-host-disease. Read more here: https://lnkd.in/g4zSDh6W
-
-
The?second From Inquiry To Action Health?Equity?Forum?is underway at the Mount Sinai?campus. Hosted by the Mount Sinai - Royalty?Pharma Alliance for Health Equity Research, the?event brings leading health?equity researchers,?community stakeholders and public policy?experts together?to?share real world evidence and?address longstanding?disparities?in healthcare?affecting at-risk communities. https://lnkd.in/eGWYFZXp
-
-
Royalty Pharma is excited to announce an agreement to acquire a royalty interest in Sanofi’s frexalimab for $525 million, including transaction costs. Frexalimab is a next generation immunology therapy in Phase 3 development for multiple sclerosis with the potential to address a wide range of immune-mediated diseases. Read more here: https://lnkd.in/e9Rms55H
-
-
Thank you to our 340+ attendees and 50+ speakers for making our 2024 Accelerating Bio-Innovation Conference a huge success! A very special thanks to the?University of Cambridge and the Cambridge Academy of Therapeutic Sciences (CATS), University of Cambridge for hosting this special event. Save the Date for the next Accelerating Bio-Innovation Conference which will take place at the Massachusetts Institute of Technology from June 23-25, 2025.?
-
The 2024 Accelerating Bio-Innovation Conference is underway! Thought leaders from across the biopharma ecosystem have come together at the?University of Cambridge to engage in crucial debates and discussions confronting pioneers in the world of biopharmaceuticals, bridging the realms of science, investing and innovative therapeutics. This year's conference features 50+ speakers addressing topics ranging from the challenges of developing new innovative therapies to the synergies of collaboration between academia, industry and risk capital.??
-
-
The inaugural From Inquiry To Action Health Equity Symposium is underway at the Mount Sinai campus. Hosted by the Mount Sinai Royalty Pharma Alliance for Health Equity Research, the event brings dozens of health equity researchers and public policy experts together to share real world evidence and address longstanding disparities in healthcare affecting at-risk communities.?
-